[1]刘冰,韩冰,袁红亮,等.血清IL-17、IL-23水平对雷公藤多苷治疗类风湿关节炎的预后评估价值[J].西部中医药,2023,36(05):143-147.[doi:10.12174/j.issn.2096-9600.2023.05.33]
　LIU Bing,HAN Bing,YUAN Hongliang,et al.Evaluation of Serum IL-17 and IL-23 in the Prognosis of Patients with Rheumatoid Arthritis Treated by Tripterygium Glycosides[J].Western Journal of Traditional Chinese Medicine,2023,36(05):143-147.[doi:10.12174/j.issn.2096-9600.2023.05.33]
点击复制

血清IL-17、IL-23水平对雷公藤多苷治疗类风湿关节炎的预后评估价值
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年05期
页码:
143-147
栏目:
出版日期:
2023-05-15

文章信息/Info

Title:
Evaluation of Serum IL-17 and IL-23 in the Prognosis of Patients with Rheumatoid Arthritis Treated by Tripterygium Glycosides
作者:
刘冰, 韩冰, 袁红亮, 汪洪波
秦皇岛市中医医院,河北 秦皇岛 066000
Author(s):
LIU Bing, HAN Bing, YUAN Hongliang, WANG Hongbo
Qinhuangdao Hospital of TCM, Qinhuangdao 066000, China
关键词:
类风湿关节炎; 白细胞介素17; 白细胞介素23; 雷公藤多苷; 预后评估
Keywords:
rheumatoid arthritis; IL-17; IL-23; tripterygium glycosides; prognosis
分类号:
R241.9
DOI:
10.12174/j.issn.2096-9600.2023.05.33
文献标志码:
B
摘要:
目的研究白细胞介素17（interleukin-17，IL-17）、白细胞介素23（interleukin-23，IL-23）对雷公藤多苷（tripterygium glycosides，TG）治疗类风湿关节炎（rheumatoid arthritis，RA）的预后评估价值。 方法120例RA患者均采用甲氨蝶呤片联合TG治疗，其中失访14例，根据治疗后6个月预后情况将患者分为良好组81例与不良组25例。比较两组患者血清IL-17、IL-23水平及其他RA预后可能的影响因素；Logistic回归分析方法分析RA预后影响因素；绘制受试者工作ROC曲线，分析血清IL-17、IL-23对RA预后的预测价值，并采用Kappa一致性检验方法分析血清IL-17联合IL-23预测RA预后的效能。 结果与良好组比较，不良组28个关节疾病活动度评分（DAS28）、人类白细胞抗原-DR4（HLA-DR4）阳性构成比，血清IL-17、IL-23水平均较高，差异有统计学意义（P＜0.05）；Logistic回归分析显示，DAS28评分、HLA-DR4阳性、IL-17、IL-23均是TG治疗RA预后不良的影响因素（P＜0.05）；ROC结果显示，血清IL-17、IL-23预测RA预后不良的最佳截断点分别为22.24 ng/L、140.67 ng/L，曲线下面积分别为0.786、0.723；血清IL-17联合IL-23预测RA预后不良的效能较高（Kappa=0.801，P＜0.05）。 结论RA患者血清IL-17、IL-23水平异常升高，两者联合检测在TG治疗RA的预后评估中具有重要价值。
Abstract:
ObjectiveTo assess the values of IL-17 and IL-23 in the prognosis of patients with rheumatoid arthritis (RA) treated by tripterygium glycosides(TG). MethodsAll 120 RA patients were treated by methotrexate tablets and TG, and 14 cases were lost, and the remaining patients were divided into 81 cases of good prognosis group and 25 cases of poor prognosis group according to the prognosis six months after the treatment. To compare the levels of IL-17 and IL-23 between both groups, and other possible influencing factors of the prognosis of RA; Logistic regression analysis method was used to analyze the influencing factors of the prognosis of RA; ROC was drawn to analyze the predictive values of IL-17 and IL-23 on the prognosis of RA, Kappa consistency test was adopted to analyze the efficacy of IL-17 and IL-23 in the prediction of RA prognosis. ResultsCompared with good prognosis group, the scores of DAS28, constituent ratio of positive HLA-DR4, the levels of IL-17 and IL-23 were higher in the poor prognosis group, and the difference had statistical meaning (P<0.05); Logistic regression analysis showed that DAS28 scores, positive HLA-DR4, IL-17 and IL-23 were the influencing factors for the poor prognosis of treating RA by TG (P<0.05); ROC results displayed that the optimal cut-off points for IL-17 and IL-23 to predict the poor prognosis of RA were 22.24 ng/L and 140.67 ng/L respectively, AUC were 0.786 and 0.723 respectively; IL-17 and IL-23 had high efficacy in predicting poor prognosis of RA (Kappa=0.801, P<0.05). ConclusionRA patients manifest abnormal increase of IL-17 and IL-23, the combined detection of both is of great value in the prognosis evaluation of treating RA with TG.

相似文献/References:

[1]马建辉,雷学峰,吕健△.中西医药物配合手法治疗类风湿性关节炎60例临床观察[J].西部中医药,2013,26(01):97.
　MA Jianhui,LEI Xuefeng,LV Jian.Integrative Medicine and Manipulation in the Treatment for 60 Cases of Rheumatoid Arthritis[J].Western Journal of Traditional Chinese Medicine,2013,26(05):97.
[2]张晓琴,何东初.复方玄驹胶囊联合甲氨蝶呤、来氟米特治疗类风湿关节炎40例[J].西部中医药,2012,25(05):78.
　ZHANG Xiao-qin,HE Dong-chu.Treatment of Rheumatoid Arthritis with Compound XuanJu Capsule combined with Methotrexate and Leflunomide: A Report of 40 Cases[J].Western Journal of Traditional Chinese Medicine,2012,25(05):78.
[3]王佳,王钢,王丽琴,等.秦艽醇提物治疗类风湿关节炎的实验研究[J].西部中医药,2015,28(07):11.
[4]刘佳,盛丽,张宝洲,等.类风湿性关节炎膝关节病变的高频超声评价[J].西部中医药,2015,28(10):134.
[5]陈慕芝,孙红艳,照日格图△.223例类风湿关节炎患者中医证候及实验室指标分析[J].西部中医药,2016,29(05):67.
　CHEN Muzhi,SUN Hongyan,ZHAORI Getu.The Analysis of Lab Indicators and TCM Patterns of 223 Patients with Rheumatoid Arthritis[J].Western Journal of Traditional Chinese Medicine,2016,29(05):67.
[6]李拥军,郭玉荣,尹智功,等.瑶药包热敷熨对类风湿关节炎患者血清白细胞介素1β及肿瘤坏死因子α的影响[J].西部中医药,2016,29(03):61.
　LI Yongjun,GUO Yurong,YIN Zhigong,et al.Influence of Yao Medicine Package Hot Ironing Therapy on IL-1β and TNF-α of the Patients with Rheumatoid Arthritis[J].Western Journal of Traditional Chinese Medicine,2016,29(05):61.
[7]徐萍,章鹏,于笑霞△.通痹胶囊治疗寒湿痹阻型类风湿性关节炎35例[J].西部中医药,2017,30(08):92.
　XU Ping,ZHANG Peng,YU Xiaoxia.TongBi Capsules in Treating 35 Cases of Rheumatoid Arthritis of Cold-dampness Impediment Pattern[J].Western Journal of Traditional Chinese Medicine,2017,30(05):92.
[8]何奕坤,杨光辉△,胥晓芳,等.类风湿关节炎继发肺间质病变的中医药治疗进展[J].西部中医药,2018,31(03):140.
　HE Yikun,YANG Guanghui,XU Xiaofang,et al.TCM Therapeutic Progress of Rheumatoid Arthritis/Interstitial Lung Disease[J].Western Journal of Traditional Chinese Medicine,2018,31(05):140.
[9]田雪梅,王海东,年芳红,等.武威汉代医简“瘀方”治疗中晚期痰瘀痹阻型类风湿关节炎验案举隅[J].西部中医药,2018,31(09):64.
　TIAN Xuemei,WANG Haidong,NIAN Fanghong,et al.Effective Cases of Treating Advanced Rheumatoid Arthritis of Phlegm-stasis Blocking Pattern by ″Stasis Prescription″ from Wuwei Medical Bamboo Slips in Han Dynasty[J].Western Journal of Traditional Chinese Medicine,2018,31(05):64.
[10]郭立霞,黄照国,闫恒志,等.清热利湿通络方联合西药治疗类风湿关节炎湿热痹阻证疗效观察[J].西部中医药,2018,31(07):83.
　GUO Lixia,HUANG Zhaoguo,YAN Hengzhi,et al.Clinical Observation on Heat-clearing Damp-eliminating Collateral-dredging Prescriptions Jointed with Western Medicine in Treating Rheumatoid Arthritis of Damp-heat Arthralgia Pattern[J].Western Journal of Traditional Chinese Medicine,2018,31(05):83.

备注/Memo

备注/Memo:
刘冰（1980—），男，副主任技师。研究方向：临床检验。秦皇岛市科学技术研究与发展计划项目（201902A066）。
更新日期/Last Update: 2023-05-15